Lecithin for Liver Health
Verdict: Insufficient Evidence
Across 3 PubMed studies, the evidence for Lecithin in Liver Health grades Tier U — unverified / insufficient. Research is still too limited to draw a firm conclusion.
U ⚫ U Unverified Insufficient Evidence
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.44
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
U · Insufficient Evidence
Confidence
78%
Broadly consistent
Evidence level
E3
Single high-quality meta-analysis
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.443
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (3)L2 · primary research & systematic reviews
II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease
Finding: PPC did not differ significantly from placebo on fibrosis progression (22.8% vs 20.0% progressing at least one stage; NS). Alcohol intake fell unexpectedly to ~2.5 drinks/day in both arms. A non-significant trend favoring PPC was seen for transaminases and bilirubin in subgroups. The trial was essentially null for the primary histological endpoint.
View on PubMed Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis
Finding: EPL plus antidiabetic therapy significantly reduced ALT (MD approx -11.28 U/L), triglycerides (MD approx -49.33 mg/dL) and total cholesterol (MD approx -29.74 mg/dL) vs therapy alone, with higher overall improvement rate (RR 1.50). Endpoints were biochemical/ultrasound, not biopsy-confirmed histology.
View on PubMed Regression of Liver Steatosis Following Phosphatidylcholine Administration: A Review of Molecular and Metabolic Pathways Involved
Finding: Narrative review proposing four mechanisms (PPARalpha-driven fatty-acid oxidation, SREBP-1 inhibition, enhanced VLDL secretion, reduced intestinal fat absorption). Authors note that despite reported clinical effects of EPL the mode of action is poorly understood and mechanisms require further in vitro/in vivo testing.
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Cautious
The ingredient is used in food as an emulsifier and emulsifier salt as defined in 184.1(j)(1)(viii) and a flavoring agent and adjuvant as defined in 170.3(o)(12) of this chapter. source↗
L4b EU EFSA
Neutral
L4d TW TFDA / 衛福部
Neutral
目前得宣稱之保健功效共有13項：「護肝」、「抗疲勞」、「調節血脂」、「調節血糖」、「免疫調節」、「骨質保健」、「牙齒保健」、「延緩衰老」、「促進鐵吸收」、「胃腸功能改善」、「輔助調節血壓」、「不易形成體脂肪」、「輔助調整過敏體質」。 source↗
L4e WHO
Not addressed
In view of biochemical and nutritional experience with lecithin, the ADI was changed to 'not limited'. [JECFA evaluation of lecithin, WHO Food Additives Series] source↗
L5a NIH Office of Dietary Supplements
Cautious
L5e Specialty Society (condition-mapped)
Not addressed